Growth differentiation factor 15 (GDF15)-mediated HER2 phosphorylation reduces trastuzumab sensitivity of HER2-overexpressing breast cancer cells. [electronic resource]
Producer: 20111216Description: 1090-9 p. digitalISSN:- 1873-2968
- Antibodies, Monoclonal, Humanized -- therapeutic use
- Antineoplastic Agents -- therapeutic use
- Breast Neoplasms -- drug therapy
- Cell Line, Tumor
- Drug Resistance, Neoplasm
- Female
- Gene Expression Regulation, Neoplastic -- drug effects
- Gene Silencing
- Growth Differentiation Factor 15 -- genetics
- Humans
- Phosphorylation -- physiology
- Proto-Oncogene Proteins pp60(c-src) -- metabolism
- Receptor, ErbB-2 -- genetics
- Receptors, Transforming Growth Factor beta -- metabolism
- Signal Transduction
- Trastuzumab
No physical items for this record
Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.